Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 12/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30575925 | 0.68 | EGFR (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL17362696 | 0.68 | EGFR (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL3933569 | 0.68 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL3933701 | 0.68 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL6416647 | 0.67 | EGFR (0.44) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL3942129 | 0.64 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL1884792 | 0.61 | — | — | |
| SCHEMBL3934420 | 0.61 | — | — | |
| SCHEMBL30194952 | 0.60 | HASPIN (0.40) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL3931332 | 0.60 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | claimed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | claimed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | claimed |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | PI4KA 2716/4885PI4K2B 3006/4885PI4K2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.